To finance the pre-clinical and clinical development of our innovative antibacterials, we are eager to acquire equity investment from local and international venture capital firms.
Since 2017, we have received two investment rounds from five regional investors:
(1) In March 2017, a pre-seed investment was acquired by from RUG Houdstermaatschappij B.V., Hanzepoort B.V., and Stichting Ir. G.J. Smid Fonds B.V.
(2) In July 2018, Pharma Connect Capital B.V. and Carduso Capital B.V. invested together with the pervious investors in the seed-funding round with the goal to bring our lead compounds into advanced pre-clinical development in 2019.
